Filing Details
- Accession Number:
- 0001104659-25-059524
- Form Type:
- 13D Filing
- Publication Date:
- 2025-06-12 20:00:00
- Filed By:
- BIOS FUND I, LP
- Company:
- Lantern Pharma Inc. (NASDAQ:LTRN)
- Filing Date:
- 2025-06-13
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| BIOS FUND I, LP | 0 | 323,335 | 0 | 323,335 | 323,335 | 3.00% |
| BIOS FUND I QP, LP | 0 | 189,117 | 0 | 189,117 | 189,117 | 1.75% |
| BIOS FUND II, LP | 0 | 114,272 | 0 | 114,272 | 114,272 | 1.06% |
| BIOS FUND II QP, LP | 0 | 373,178 | 0 | 373,178 | 373,178 | 3.46% |
| BIOS FUND II NT, LP | 0 | 49,957 | 0 | 49,957 | 49,957 | 0.46% |
| BP DIRECTORS, LP | 0 | 26,093 | 0 | 26,093 | 26,093 | 0.24% |
| BIOS EQUITY PARTNERS, LP | 0 | 538,545 | 0 | 538,545 | 538,545 | 4.99% |
| BIOS EQUITY PARTNERS II, LP | 0 | 537,407 | 0 | 537,407 | 537,407 | 4.98% |
| CAVU MANAGEMENT, LP | 0 | 1,075,952 | 0 | 1,075,952 | 1,075,952 | 9.98% |
| BIOS CAPITAL MANAGEMENT, LP | 0 | 1,075,952 | 0 | 1,075,952 | 1,075,952 | 9.98% |
| CAVU ADVISORS, LLC | 0 | 1,075,952 | 0 | 1,075,952 | 1,075,952 | 9.98% |
| BIOS ADVISORS GP, LLC | 0 | 1,075,952 | 0 | 1,075,952 | 1,075,952 | 9.98% |
| LESLIE W. KREIS | 0 | 1,075,952 | 0 | 1,075,952 | 1,075,952 | 9.98% |
| AARON G.L. FLETCHER | 0 | 1,075,952 | 0 | 1,075,952 | 1,075,952 | 9.98% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 4)
|
Lantern Pharma Inc. (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
51654W101 (CUSIP Number) |
Bios Equity Partners, LP 1751 River Run, Suite 400, Fort Worth, TX, 76107 (817) 984-9197 Rick Jordan; Polsinelli PC 4020 Maple Avenue, Suite 300, Dallas, TX, 75219 (214) 397-0030 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
06/12/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS FUND I, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
 (b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
323,335.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
3.00 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of shares of common stock, par value $0.0001 per share ("Shares") directly held by Bios Fund I, LP ("Bios Fund I").
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS FUND I QP, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
189,117.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
1.75 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of Shares directly held by Bios Fund I QP, LP ("Bios Fund I QP").
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS FUND II, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
114,272.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
1.06 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of Shares directly held by Bios Fund II, LP ("Bios Fund II").
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS FUND II QP, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
373,178.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
3.46 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of Shares directly held by Bios Fund II QP, LP ("Bios Fund II QP").
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS FUND II NT, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
49,957.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.46 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of Shares directly held by Bios Fund II NT, LP ("Bios Fund II NT").
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BP DIRECTORS, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
26,093.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.24 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of Shares directly held by BP Directors, LP ("BP Directors").
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS EQUITY PARTNERS, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
538,545.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.99 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP and (iii) 26,093 Shares directly held by BP Directors. Bios Equity Partners, LP ("Bios Equity I") is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. In its capacity as the general partner of these entities, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to securities directly held by these entities.
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS EQUITY PARTNERS II, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
537,407.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.98 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 114,272 Shares directly held by Bios Fund II, (ii) 373,178 Shares directly held by Bios Fund II QP and (iii) 49,957 Shares directly held by Bios Fund II NT. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities.
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
CAVU MANAGEMENT, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,075,952.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
9.98 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Cavu Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities").
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS CAPITAL MANAGEMENT, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,075,952.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
9.98 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Bios Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
CAVU ADVISORS, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,075,952.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
9.98 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management, and therefore may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS ADVISORS GP, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,075,952.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
9.98 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
LESLIE W. KREIS | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF, OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,075,952.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
9.98 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
AARON G.L. FLETCHER | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF, OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
1,075,952.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
9.98 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN, OO |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.
Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $0.0001 per share | |
| (b) | Name of Issuer:
Lantern Pharma Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS,
TEXAS
, 75201. | |
Item 1 Comment:
This Amendment No. 4 hereby amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "Commission") on June 15, 2020 (the "Original Schedule 13D"), as amended by the statement on Schedule 13D/A filed with the Commission on March 22, 2022 ("Amendment No. 1"), as further amended by the statement on Schedule 13D/A filed with the Commission on December 1, 2023 ("Amendment No. 2"), as further amended by the statement on Schedule 13D/A filed with the Commission on March 1, 2024 ("Amendment No. 3" and, together with the Original Schedule 13D, Amendment No. 1 and Amendment No. 2, the "Prior Statements"). The securities to which the Schedule 13D relates are the shares of common stock, par value $0.0001 per share (the "Shares"), of Lantern Pharma, Inc., a Delaware corporation (the "Issuer"). | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. | |
| (b) | The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. | |
| (c) | On May 27, 2025, (i) Bios Fund I sold 6,479 Shares, Bios Fund I QP sold 3,790 Shares, (iii) Bios Fund II sold 2,290 Shares, (iv) Bios Fund II QP sold 7,478 Shares and (v) Bios Fund II NT sold 1,000 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $3.05 on the open market at prices ranging between $2.87 to $3.21, inclusive.
On May 28, 2025, (i) Bios Fund I sold 4,620 Shares, Bios Fund I QP sold 2,702 Shares, (iii) Bios Fund II sold 1,632 Shares, (iv) Bios Fund II QP sold 5,332 Shares and (v) Bios Fund II NT sold 714 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $2.87 on the open market at prices ranging between $2.85 to $2.94, inclusive.
On May 29, 2025, (i) Bios Fund I sold 6,221 Shares, Bios Fund I QP sold 3,639 Shares, (iii) Bios Fund II sold 2,199 Shares, (iv) Bios Fund II QP sold 7,180 Shares and (v) Bios Fund II NT sold 961 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $3.03 on the open market at prices ranging between $3.00 to $3.13, inclusive.
On June 10, 2025, (i) Bios Fund I sold 5 Shares, Bios Fund I QP sold 3 Shares, (iii) Bios Fund II sold 2 Shares, (iv) Bios Fund II QP sold 5 Shares and (v) Bios Fund II NT sold 1 Share, all such sales in clauses (i)-(v) of this sentence being sold at a price of $3.40 on the open market.
On June 11, 2025, (i) Bios Fund I sold 293 Shares, Bios Fund I QP sold 171 Shares, (iii) Bios Fund II sold 103 Shares, (iv) Bios Fund II QP sold 338 Shares and (v) Bios Fund II NT sold 45 Shares, all such sales in clauses (i)-(v) of this sentence being sold at a price of $3.40 on the open market.
On June 12, 2025, (i) Bios Fund I sold 18,678 Shares, Bios Fund I QP sold 10,925 Shares, (iii) Bios Fund II sold 6,601 Shares, (iv) Bios Fund II QP sold 21,557 Shares and (v) Bios Fund II NT sold 2,886 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $3.38 on the open market at prices ranging between $3.25 to $3.57, inclusive.
On June 13, 2025, (i) Bios Fund I sold 12,319 Shares, Bios Fund I QP sold 7,206 Shares, (iii) Bios Fund II sold 4,354 Shares, (iv) Bios Fund II QP sold 14,218 Shares and (v) Bios Fund II NT sold 1,903 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $3.09 on the open market at prices ranging between $3.05 to $3.26, inclusive.
The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above. | |
| (d) | Except as described in this Amendment No. 4, to the knowledge of the Reporting Persons, only the Reporting Persons have the right to receive or the power to direct receipt of dividends from, or proceeds from the sale of, the Shares reported by the Schedule 13D. | |
| (e) | Not applicable. | |
| Item 7. | Material to be Filed as Exhibits. | |
Exhibit 99.1: Joint Filing Agreement, dated June 23, 2020 (incorporated by reference to the Original Schedule 13D, filed on June 23, 2020). | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comments accompanying signature:
John Fucci is signing on behalf of the Reporting Persons pursuant to a power of attorney dated May 22, 2025, 2024, which was previously filed with the Commission as an exhibit to Forms 4 filed by the Reporting Persons on May 29, 2025 (SEC File No. 001-39318) |